RedHill Biopharma Ltd. (NASDAQ:RDHL)’s traded shares stood at 2.21 million during the last session, with the company’s beta value hitting 2.26. At the close of trading, the stock’s price was $0.18, to imply a decrease of -0.56% or $0.0 in intraday trading. The RDHL share’s 52-week high remains $3.27, putting it -1716.67% down since that peak but still an impressive 27.78% since price per share fell to its 52-week low of $0.13. The company has a valuation of $17.09M, with an average of 2.02 million shares in intraday trading volume over the past 10 days and average of 6.42 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for RedHill Biopharma Ltd. (RDHL), translating to a mean rating of 2.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give RDHL a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at $0.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
RedHill Biopharma Ltd. (NASDAQ:RDHL) trade information
After registering a -0.56% downside in the last session, RedHill Biopharma Ltd. (RDHL) has traded red over the past five days. The stock hit a weekly high of 0.2170 this Wednesday, 03/15/23, dropping -0.56% in its intraday price action. The 5-day price performance for the stock is -14.76%, and -14.76% over 30 days. With these gigs, the year-to-date price performance is 27.58%. Short interest in RedHill Biopharma Ltd. (NASDAQ:RDHL) saw shorts transact 8.11 million shares and set a 0.64 days time to cover.
Analysts on Wall Street suggest a consensus price target of $1.00, implying an increase of 82.0% to the stock’s current value. The extremes give us $1.00 and $1.00 for target low and target high price respectively. As such, RDHL has been trading -455.56% off suggested target high and -455.56% from its likely low.
RedHill Biopharma Ltd. (RDHL) estimates and forecasts
Looking at statistics comparing RedHill Biopharma Ltd. share performance against respective industry, we note that the company has outperformed competitors. RedHill Biopharma Ltd. (RDHL) shares are -78.57% down over the last 6 months, with its year-to-date growth rate higher than industry average at 69.05% against 11.00%. The rating firms project that company’s revenue will grow 3.60% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is $21.24 million. Meanwhile, for the quarter ending Dec 2022, a total of 1 analyst(s) estimate revenue growth to $18.1 million.Earnings reports from the last fiscal year show that sales brought in $21.61 million and $22.07 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -1.70% before dropping -18.00% in the following quarter.
RedHill Biopharma Ltd. has its next earnings report out between March 15 and March 20. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. RedHill Biopharma Ltd. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
RedHill Biopharma Ltd. (NASDAQ:RDHL)’s Major holders
RedHill Biopharma Ltd. insiders hold 7.56% of total outstanding shares, with institutional holders owning 19.92% of the shares at 21.55% float percentage. In total, 19.92% institutions holds shares in the company, led by Millennium Management Llc. As of Sep 29, 2022, the company held over 0.62 million shares (or 0.97% of shares), all amounting to roughly $0.31 million.
The next major institution holding the largest number of shares is Morgan Stanley with 0.39 million shares, or about 0.60% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $0.19 million.
We also have Fidelity NASDAQ Composite Index Fund and Trust For Professional Managers-PMC Diversified Equity Fund as the top two Mutual Funds with the largest holdings of the RedHill Biopharma Ltd. (RDHL) shares. Going by data provided on Nov 29, 2022, Fidelity NASDAQ Composite Index Fund holds roughly 41637.0 shares. This is just over 0.07% of the total shares, with a market valuation of $14989.0. Data from the same date shows that the other fund manager holds a little less at 45512.0, or 0.07% of the shares, all valued at about 6385.0.